Sanofi-Aventis Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Sanofi-Aventis covers the month of January 2005. The report incorporates by reference two press releases issued on January 25 and January 26, 2005, regarding fourth quarter and full-year 2004 sales results and a legal challenge to a key patent.
Key Financial Metrics
The filing text itself does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the attached press release (Exhibit 99.1) which is referenced but not detailed in the provided text.
Material Changes and Unusual Items
- Patent Challenge: On January 25, 2005, the company announced a challenge to the UK patent of Plavix® (Exhibit 99.2).
- Sales Announcement: On January 26, 2005, the company announced fourth quarter and full-year 2004 sales results (Exhibit 99.1).
Guidance, Outlook, and Risks
The filing text does not contain specific management commentary, forward-looking guidance, or detailed risk factors. The primary risk highlighted by the filing is the legal challenge to the Plavix® patent in the UK, which could impact future revenue streams for this product.
Investor Verification Checklist
- Verify the specific fourth quarter and full-year 2004 sales figures in the attached press release (Exhibit 99.1).
- Assess the potential financial impact of the UK patent challenge on Plavix® (Exhibit 99.2).
- Review the full text of the press releases to understand management's commentary on the 2004 performance.